[go: up one dir, main page]

AR027624A1 - Forma de dosificacion oral para la administracion de la combinacion de tegafur, uracilo y acido folinico, y oxaliplatino y metodo de uso de los mismos - Google Patents

Forma de dosificacion oral para la administracion de la combinacion de tegafur, uracilo y acido folinico, y oxaliplatino y metodo de uso de los mismos

Info

Publication number
AR027624A1
AR027624A1 ARP010101100A ARP010101100A AR027624A1 AR 027624 A1 AR027624 A1 AR 027624A1 AR P010101100 A ARP010101100 A AR P010101100A AR P010101100 A ARP010101100 A AR P010101100A AR 027624 A1 AR027624 A1 AR 027624A1
Authority
AR
Argentina
Prior art keywords
administration
tegafur
oxaliplatin
dosage form
uracilo
Prior art date
Application number
ARP010101100A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR027624A1 publication Critical patent/AR027624A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente proporciona una forma de dosificacion y un método de administracion de una composicion anti-tumor que comprende tegafur, uracilo y ácidofolínico para potenciar la coadministracion de oxaliplatino.
ARP010101100A 2000-03-08 2001-03-08 Forma de dosificacion oral para la administracion de la combinacion de tegafur, uracilo y acido folinico, y oxaliplatino y metodo de uso de los mismos AR027624A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18784200P 2000-03-08 2000-03-08
US23114700P 2000-09-08 2000-09-08

Publications (1)

Publication Number Publication Date
AR027624A1 true AR027624A1 (es) 2003-04-02

Family

ID=26883457

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101100A AR027624A1 (es) 2000-03-08 2001-03-08 Forma de dosificacion oral para la administracion de la combinacion de tegafur, uracilo y acido folinico, y oxaliplatino y metodo de uso de los mismos

Country Status (5)

Country Link
US (1) US6602870B2 (es)
AR (1) AR027624A1 (es)
AU (1) AU2001240001A1 (es)
PE (1) PE20020769A1 (es)
WO (1) WO2001066102A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476068B1 (en) 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
FR2834641B1 (fr) * 2002-01-14 2005-04-22 Ct Regional De Lutte Contre Le Protection de la neurotoxicite de l'oxaliplatine par administration de calcium et de magnesium
PT1604991E (pt) * 2003-03-14 2008-10-27 Taiho Pharmaceutical Co Ltd Potenciador do efeito antitumoral e agente antitumoral
KR100844477B1 (ko) * 2004-06-09 2008-07-07 다이호야쿠힌고교 가부시키가이샤 항종양 효과 증강제, 항종양제 및 암 치료 방법
CN103054871A (zh) * 2004-06-09 2013-04-24 大鹏药品工业株式会社 抗肿瘤效果增强剂、抗肿瘤剂和癌治疗方法
US20080081301A1 (en) * 2006-10-03 2008-04-03 Hannum Mark C Low NOx combustion
CN101657203B (zh) * 2007-03-02 2012-09-05 卧龙岗大学 抗癌药的组合物及递送方法
US8007470B2 (en) * 2007-07-10 2011-08-30 Cook Medical Technologies Llc Minimally invasive medical device and method for delivery of therapeutic or diagnostic agents into a vessel wall
AU2008356312B2 (en) * 2008-05-12 2015-04-09 Shizuoka Prefecture Antitumor agent, kit, and method for treating cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328229A (en) 1978-03-29 1982-05-04 Taiho Pharmaceutical Company Limited Anti-cancer composition for delivering 5-fluorouracil to cancer tissues
US5534513A (en) 1991-09-05 1996-07-09 Taiho Pharmaceutical Company, Ltd. Antitumor potentiator and antitumor composition

Also Published As

Publication number Publication date
WO2001066102A3 (en) 2001-12-20
WO2001066102A2 (en) 2001-09-13
US20020045632A1 (en) 2002-04-18
US6602870B2 (en) 2003-08-05
PE20020769A1 (es) 2002-09-06
AU2001240001A1 (en) 2001-09-17

Similar Documents

Publication Publication Date Title
AR011069A1 (es) Compuestos amidino, proceso para su preparacion, compuestos intermediarios, formulaciones farmaceuticas que los comprenden, y su uso en la fabricacion de un medicamento como inhibidor de la oxido nitrico sintasa inducible.
IS6614A (is) Ný tríasólpýrimídínefnasambönd
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
ES2191682T3 (es) Nueva formulacion farmaceutica.
ES2161085T3 (es) Formulaciones que contienen oxaliplatino.
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
AR033555A1 (es) Producto para el tratamiento del carcinoma de receptor de estrogeno positivo, y uso de dicho producto para preparar medicamentos
BR0214199A (pt) Composições de fenóxi amina para liberar agentes ativos, forma de unidade de dosagem e método de administração
ES2195785B1 (es) Nuevos derivados de piridazin-3(2h)-ona.
SE9802208D0 (sv) Novel compounds
AR047191A1 (es) Metodos de tratamiento de fibrosis hepatica
HN2003000183A (es) Difenilazetidinonas sustituidas en anillo procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso.
AR027624A1 (es) Forma de dosificacion oral para la administracion de la combinacion de tegafur, uracilo y acido folinico, y oxaliplatino y metodo de uso de los mismos
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
PT1105105E (pt) Forma de administracao oral para piridin-2-ilmetilsulfinil-1h-benzimidazois
AR029347A1 (es) Compuesto de adenina, compuesto de isognanina y 2,6-ditioxantina como precursor del mismo, uso de dichos compuestos para preparar una composicion farmaceutica y dicha composicion farmaceutica
UY25357A1 (es) Nuevos pentasacáridos, procedimiento para su preparación y composiciones farmacéuticas que los contienen.
DE50212646D1 (de) Verwendung von selenithältigen verbindungen zur topischen oder bukkalen anwendung
DOP2002000457A (es) Tetrahidroquinolinas
ES2091126T3 (es) Nuevos compuestos biciclicos de pirimidina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
AR030662A1 (es) Beta-tio-alfa-aminoacidos, procedimiento para su fabricacion, medicamentos que contienen estos compuestos y el uso de los tioaminoacidos para la preparacion de medicamentos
SE9802209D0 (sv) Novel compounds
IT1317049B1 (it) Composti utili per la preparazione di medicamenti ad attivita'inibitrice della fosfodiesterasi iv.
UY26607A1 (es) Forma de dosificación oral para la administración de la combinación de tegafur, uracilo y ácido folínico, y oxaliplatino y método de uso de los mismos
MX9204212A (es) Preparado de combinacion farmaceutico.

Legal Events

Date Code Title Description
FB Suspension of granting procedure